Sarepta Therapeutics (SRPT) Stock Price, News & Analysis

Company Overview

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is a biotechnology company focused on developing and commercializing precision genetic medicines for rare diseases. Its research programs include RNA-based therapies, gene therapy and other genetic medicine approaches designed to address the underlying causes of serious genetic disorders.

The company’s primary commercial focus has been Duchenne muscular dystrophy (DMD). Sarepta markets Exondys 51, Vyondys 53 and Amondys 45, exon-skipping therapies for certain patients with DMD mutations, as well as Elevidys, a gene therapy for eligible patients with Duchenne muscular dystrophy. The availability and approved uses of these products may vary by jurisdiction and patient population.

Sarepta was originally established as AntiVirals and later operated as AVI BioPharma before adopting the Sarepta Therapeutics name in 2012. Headquartered in Cambridge, Massachusetts, the company conducts research and commercial activities in the United States and serves patients and healthcare providers through its therapies and related support programs, while continuing to develop treatments for additional rare genetic diseases.

Key Stats

• Today's Range: $16.37 to $16.91
• 50-Day Range: $16.51 to $23.21
• 52-Week Range: $14.68 to $24.68
• Volume: 2.74 million shs
• Average Volume: 2.81 million shs
• Market Capitalization: $1.78 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.59
• Consensus Rating: Reduce

Sarepta Therapeutics Stock Analysis - MarketRank™

Sarepta Therapeutics scored higher than 67% of companies evaluated by MarketBeat, and ranked 265th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Reduce

Consensus Rating

Sarepta Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.95, and is based on no strong buy ratings, 7 buy ratings, 6 hold ratings, and 8 sell ratings.

Upside Potential

Sarepta Therapeutics has a consensus price target of $22.59, representing about 34.2% upside from its current price of $16.83.

Amount of Analyst Coverage

Sarepta Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: -59.02%

Earnings Growth

Earnings for Sarepta Therapeutics are expected to decrease by -59.02% in the coming year, from $3.27 to $1.34 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Sarepta Therapeutics is -5.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sarepta Therapeutics is -5.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Sarepta Therapeutics has a PEG Ratio of 0.30. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Sarepta Therapeutics has a P/B Ratio of 1.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

23.17% of the float of Sarepta Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Sarepta Therapeutics has a short interest ratio ("days to cover") of 8.62.

Change versus previous month

Short interest in Sarepta Therapeutics has recently decreased by 10.42%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sarepta Therapeutics does not currently pay a dividend.

Dividend Growth

Sarepta Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.12

News Sentiment

Sarepta Therapeutics has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Sarepta Therapeutics this week, compared to 8 articles on an average week.

Search Interest

Only 7 people have searched for SRPT on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.

MarketBeat Follows

5 people have added Sarepta Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sarepta Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.90% of the stock of Sarepta Therapeutics is held by insiders.

Percentage Held by Institutions

86.68% of the stock of Sarepta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 10/14/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:SRPT
• Previous Symbol: NASDAQ:AVII
• CIK: 873303
• Web: www.sarepta.com
• Phone: (617) 274-4000
• Fax: 425-354-5038
• Employees: 835
• Year Founded: 1980

Price Target and Rating

• Average Price Target for Sarepta Therapeutics: $22.59
• High Price Target: $38.00
• Low Price Target: $5.00
• Potential Upside/Downside: +34.2%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.95
• Research Coverage: 21 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.90)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 5.15
• P/E Growth: 0.3
• Net Income: -$713.41 million
• Net Margins: -13.48%
• Pretax Margin: -6.63%
• Return on Equity: -1.60%
• Return on Assets: -0.66%

Debt

• Debt-to-Equity Ratio: 0.55
• Current Ratio: 4.42
• Quick Ratio: 2.62

Sales & Book Value

• Annual Sales: $2.20 billion
• Price / Sales: 0.81
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $10.89 per share
• Price / Book: 1.55

Miscellaneous

• Outstanding Shares: 105,630,000
• Free Float: 98,339,000
• Market Cap: $1.78 billion
• Optionable: Optionable
• Beta: 0.38